PETAL: a global view on R/R T-/NK-lymphoma treatment reality

In this issue of Blood Advances, Han et al 1 report outcomes and prognoses for relapsed/refractory (R/R) mature T-cell lymphoma (MTCL) and mature natural killer (NK)-cell lymphoma (MNKCL) from 13 institutions in 10 countries around the globe.This international retrospective cohort study, the Peripheral T-Cell Lymphoma (PETAL) consortium, analyzed 925 patients with R/R MTCL and MNKCL, to address the pertinent lack of robust strata that would explain the heterogeneous second-line treatment responses and that would aid in decisions on subset-specific therapeutic choices.Given the often poor prognosis of this heterogeneous group of rare lymphomas in light of only few efficient treatment options, such an effort is to be applauded.PETAL profits from several incorporated valuable initiatives of systematic data collections (ie, T-cell lymphoma registries).